Fundraising Fox

Abcuro

Newton, US · Delaware corporation · 15 known investors

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis. The company is a clinical-stage biopharmaceutical firm running Phase 2/3 trials of its immunology treatments.

BiotechHealthtech

Founders & leadership

SA
Steven A. GreenbergChief Scientific Advisor & Co-Founder
SA
Steven A. Greenberg, MDChief Scientific Advisor & Co-Founder
JA
John Alexander MartinExecutive
SG
Stefano GullaExecutive
ET
Evan ThompsonExecutive
DD
David de GraafExecutive
AM
Alex MartinChief Executive Officer
KT
Karen TubridyChief Operating Officer
HJ
H. Jeffrey WilkinsChief Medical Officer
AM
Alex Martin, MBAChief Executive Officer

Board

MPMichele Park
Michele ParkBoard directorPartner at New Enterprise Associates (NEA)
JHJason Hafler
Jason HaflerinBoard directorManaging Director at Sanofi Ventures

Investors · 15

Bain Capital Life Sciences✓ verifiedBoston
New Enterprise Associates (NEA)✓ verifiedMenlo Park · $200K – $40M
RA Capital✓ verifiedBoston
Samsara BioCapital✓ verifiedPalo Alto
Sanofi Ventures✓ verifiedCambridge · $5Mvia Jason P. Hafler · board
Mass General Brigham Ventures✓ verifiedBoston
REDMILE✓ verifiedSan Francisco
Pontifax Venture CapitalHerzeliya · $6.3M – $128Mvia Tomer Kariv · board
ShangBay Capital LLCPalo Alto
abrdn plcreportedEdinburgh
Eurofarma Venturesreported
Foresite CapitalreportedWest Hollywood
New Leaf Venture Partnersreported · 2 sourcesNew York
Rock Springs CapitalreportedBaltimore
Soleus CapitalreportedGreenwich

Reported raises · per SEC filings

Form D private placements

$265.3M disclosed across 6 rounds · 2016–2026

▶$39.4MraisedAug 2026 · 23 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John Alexander MartinExecutive Officer, Director
  • Mark PruzanskiDirector
  • Ron HuntDirector
  • Michael DybbsDirector
  • Ming FangDirector
  • Sarah BoyceDirector
Offering amount
$176.5M
Amount sold
$39.4M
First sale
Aug 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$80MraisedFeb 2025 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John Alexander MartinExecutive Officer, Director
  • Sarah BoyceDirector
  • Michele ParkDirector
  • Mark PruzanskiDirector
  • Jason HaflerDirector
  • Rajeev ShahDirector
  • Ming FangDirector
  • Michael DybbsDirector
Offering amount
$200M
Amount sold
$80M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$120.1MraisedAug 2023 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Julius KnowlesDirector
  • Donald McCarthyDirector
  • Rajeev ShahDirector
  • John Alexander MartinExecutive Officer, Director
  • Tomer KarivDirector
  • Jason HaflerDirector
  • Richard MotschwillerExecutive Officer
  • Darlene Deptula-HicksDirector
Offering amount
$199.5M
Amount sold
$120.1M
First sale
Aug 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.5MraisedJan 2021 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stefano GullaExecutive Officer
  • Jason HaflerDirector
  • Ryan BerryDirector
  • Donald McCarthyDirector
  • John EdwardsDirector
  • Yajun XuDirector
  • Julius KnowlesDirector
  • Evan ThompsonExecutive Officer
  • David de GraafExecutive Officer, Director
  • Iyona RajkomarDirector
Offering amount
$42M
Amount sold
$15.5M
First sale
Jun 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedNov 2018 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • K. Evan ThompsonExecutive Officer, Director
  • Robert MillmanDirector
  • Yajun XuDirector
  • Stefano GullaExecutive Officer, Director
  • Julius KnowlesDirector
  • Nalan UtkuDirector
Offering amount
$8M
Amount sold
$8M
Proceeds to insiders
$880K
First sale
Nov 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.3MraisedDec 2016 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yajun XuDirector
  • Julius KnowlesDirector
  • Stefano GullaExecutive Officer, Director
  • K. Evan ThompsonExecutive Officer, Director
Offering amount
$2.3M
Amount sold
$2.3M
Proceeds to insiders
$500K
First sale
Nov 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Bioworld17 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Cour Pharma12 shared keywordsCOUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function. The company is advancing a pipeline of disease-modifying therapies aimed at patients with a range of autoimmune conditions.

Companies competing with Abcuro for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Abcuro secures $66m to support clinical trial of ulviprubart for IBMclinicaltrialsarena.com · Aug 2026Etched's $21b valuation, Smack's battlefield software, and Goldman's real estate buyaxios.com · Aug 2026Abcuro Announces $66 Million Series D Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositisfinance.yahoo.com · Aug 2026Abcuro Announces $66 Million Series D Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis - BioSpacebiospace.com · Aug 2026Abcuro Raises $66M in Series D Fundingfinsmes.com · Aug 2026Abcuro raises $66M to fund a Phase 3 trial in a muscle- ...x.com · Aug 2026Abcuro Raises $66 Million for New Phase 3 Ulviprubart Study in IBM Abcuro Raises $66M for New Ulviprubart Phase 3 IBM Trialcureibm.org · Aug 2026Abcuro | Biotechnology | The Pharmaletterthepharmaletter.com · Feb 2026

Frequently asked questions

What does Abcuro do?
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis. The company is a clinical-stage biopharmaceutical firm running Phase 2/3 trials of its immunology treatments.
Who founded Abcuro?
Abcuro was founded by Steven A. Greenberg, Steven A. Greenberg, MD.
Who are Abcuro's investors?
Abcuro's investors include Bain Capital Life Sciences, New Enterprise Associates (NEA), RA Capital, Samsara BioCapital, Sanofi Ventures, Mass General Brigham Ventures, REDMILE, Pontifax Venture Capital and 7 more.
How much funding has Abcuro raised?
Abcuro has disclosed $265.3M raised across 6 rounds.
Where is Abcuro headquartered?
Abcuro is headquartered in Newton, US.